关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024 年度利润分配方案，每 10 股派发现金红利人民币 9.8169 元（含税）。 此次利润分配方案以 2024 年度实施权益分派股权登记日的总股本为基 数，具体日期将在权益分派实施公告中明确。在实施权益分派股权登记日前公司 总股本发生变动的，按照每股分配金额不变的原则进行分配，相应调整分配总额， 并将另行公告具体调整情况。 此次利润分配方案未触及《上海证券交易所股票上市规则》（以下简称 "《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他风 险警示的情形。 证券代码：603259 证券简称：药明康德 公告编号：临 2025-007 无锡药明康德新药开发股份有限公司 一、利润分配方案内容 （一）2024 年度利润分配方案的具体内容 经德勤华永会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）2024 年度实现 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 分配方案：每 10 股派发现金红利人民币 3.5000 元（含税）。 此次回报股东特别分红方案以实施此次权益分派股权登记日的总股本 为基数，具体日期将在权益分派实施公告中明确。在实施权益分派股权登记日前 公司总股本发生变动的，按照每股分配金额不变的原则进行分配，相应调整分配 总额，并将另行公告具体调整情况。 一、特别分红方案 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2024 年 12 月 25 日公告通过其全资子公司 WuXi ATU (Ireland) Holding Limited、 WuXi ATU (Hong Kong) Limited 向 Altaris LLC（包括其所控制的主体）转让 WuXi ATU 业务的美国及英国运营主体的全部股权，并于 2025 年 3 月 7 日（美国时间） 完成交割。该部分业务的出售主要是为了确保所有迫切需要 WuXi ATU 细胞治 疗服务的客户和患者得到不受中断的服务和及时救治，同时 WuX ...

无锡药明康德新药开发股份有限公司 关于提请股东大会授权董事会制定中期分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"）根据《中华人民 共和国公司法》《上市公司章程指引》《上市公司监管指引第 3 号——上市公司 现金分红》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等相 关法律、法规、规范性文件及《无锡药明康德新药开发股份有限公司章程》规定， 为进一步提高分红频次，增强投资者回报水平，结合公司实际情况，公司董事会 提请股东大会授权董事会，在授权范围内制定并实施公司 2025 年中期分红方案， 具体安排如下： 一、2025 年中期现金分红安排 1、中期分红的前提条件为： （1）公司在当期盈利、累计未分配利润为正；（2）公司现金流可以满足正 常经营和持续发展的要求。 证券代码：603259 证券简称：药明康德 公告编号：临 2025-009 1 公司于 2025 年 3 月 17 日召开第三届董事会第十七次会议暨 2024 年年度董 事会会议和第三届监 ...

WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 (1)建議變更本公司的註冊資本； 及 (2)建議修訂《公司章程》 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2019年8月5日的通 函（「該通函」）；及(ii)本公司於2023年5月26日、2024年3月8日、2024年5月23日、 2024年9月10日及2024年9月27日的公告（「該等公告」），內容有關（其中包括） (a)2019年A股激勵計劃調整後首次授予股票期權第三個行權期行權條件成就； 及(b)第二次及第三次回購本公司A股及該等回購註銷完成。除非文義另有所指， 否則該通函及該等公告所界定的詞語在本公告具有相同涵義。 本公司董事會（「董事會」）謹此宣佈，於2025年3月17日，董事會在第三屆董事 會第十七次會議上議決及批准（其中包括）建 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported a revenue of RMB 39,241.4 million, a decrease of 2.7% compared to RMB 40,340.8 million in 2023[2]. - The net profit attributable to the parent company was RMB 9,352.6 million, down 12.5% from RMB 10,690.2 million in the previous year[2]. - Gross profit for the reporting period was RMB 16,016.1 million, a decrease of 2.2% year-on-year, with a gross margin of 40.8%[17]. - The adjusted net profit attributable to the parent company for the year ended December 31, 2024, was RMB 9,352.6 million, a decrease of 12.5% from RMB 10,690.2 million in 2023[41]. - The adjusted gross profit for the year ended December 31, 2024, was RMB 16,326.3 million, down 3.6% from RMB 16,937.8 million in 2023, with a gross margin of 41.6% compared to 42.0% in the previous year[41]. - The company reported a total comprehensive income of RMB 9,654,674 thousand for the year, down from RMB 10,884,792 thousand in the previous year[139]. - Basic earnings per share for the year was RMB 3.88, compared to RMB 3.83 for the previous year, indicating a marginal increase[137]. Customer and Market Insights - The company had approximately 6,000 active customers by the end of 2024, with 5,500 in continuing operations and 1,000 new customers added during the year[7]. - Revenue from the top 20 global pharmaceutical companies amounted to RMB 16.64 billion, with a year-on-year growth of 24.1% excluding COVID-19 commercialization projects[7]. - Revenue from U.S. customers was RMB 25.02 billion, a 7.7% increase excluding COVID-19 commercialization projects, while revenue from European customers grew by 14.4% to RMB 5.23 billion[7]. - The company has approximately 6,000 active clients as of the end of 2024, covering all of the top 20 global pharmaceutical companies[67]. Business Segments Performance - The company’s revenue from its chemistry business was RMB 29,052.4 million, a slight decrease of 0.4% from RMB 29,171.5 million in 2023[10]. - The testing business achieved revenue of RMB 56.7 billion, with TIDES business revenue reaching RMB 58.0 billion, a year-on-year increase of 70.1%[13]. - Clinical CRO and SMO business revenue was RMB 18.1 billion, a year-on-year increase of 2.8%, with SMO business growing by 15.4%[13]. - WuXi Biology generated revenue of RMB 25.4 billion, remaining stable year-on-year, with expectations for a 10%-15% growth in 2025[14]. Cash Flow and Investments - For the fiscal year ending December 31, 2024, the net cash generated from operating activities was RMB 11,986.8 million, a decrease of 5.2% compared to RMB 12,641.2 million for the fiscal year ending December 31, 2023[29]. - The net cash used in investing activities for the fiscal year ending December 31, 2024, was RMB (5,098.0) million, a decrease of 25.2% from RMB (6,817.0) million in the previous year, primarily due to timing differences in capital expenditures[29]. - The company made additional investments of RMB 12.2 million in joint ventures and associates during the reporting period to enhance synergies and expand its customer base[48]. - New investments outside of joint ventures and associates totaled RMB 372.1 million, with significant changes in the fair value of investments reported[50]. Dividends and Shareholder Returns - The company plans to distribute a final dividend of RMB 9.8169 per 10 shares, totaling RMB 2,835,113,437.82[3]. - A special dividend of RMB 3.5000 per 10 shares is proposed for 2025, amounting to RMB 1,010,797,403.70[4]. - The proposed cash dividend for 2024 is RMB 9.8169 per 10 shares, compared to RMB 9.8974 per 10 shares in 2023, indicating a slight decrease in the dividend payout[173]. Financial Position and Liabilities - As of December 31, 2024, total liabilities amounted to RMB 21,240.2 million, an increase from RMB 18,151.9 million as of December 31, 2023, with a debt-to-asset ratio of 26.4% compared to 24.6% in the previous year[32]. - The company reported a significant reduction in current bank borrowings, which decreased by 65.6% to RMB 1,278.6 million in 2024 from RMB 3,721.6 million in 2023[45]. - The total amount of liabilities related to derivative financial instruments decreased by 59.7% to RMB 202.0 million in 2024 from RMB 501.9 million in 2023[45]. Strategic Initiatives and Future Outlook - The company aims to enhance its capabilities and scale globally to empower pharmaceutical innovation[63]. - The company is focused on attracting and retaining top talent by reforming its reward and incentive systems, providing real promotion opportunities, and offering competitive compensation packages[97]. - The company will continue to invest heavily in new drug development technologies, focusing on various new molecular types such as peptides, oligonucleotides, PROTACs, and conjugated drugs[95]. - The overall revenue forecast for 2025 is projected to be between RMB 415 billion and RMB 430 billion[14]. Risks and Challenges - The company faces risks from a potential decline in demand for pharmaceutical R&D services, which could negatively impact its business if industry growth slows or outsourcing ratios decrease[101]. - The company is exposed to regulatory risks due to the highly regulated nature of the pharmaceutical R&D services industry, requiring timely adjustments to its business strategies[102]. - The company acknowledges the increasing competition in the global pharmaceutical R&D services market, which may weaken its competitive advantages if not addressed[104].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 子公司之間提供擔保 本公告乃由無錫藥明康德新藥開發股份有限公司（「本公司」，連同其附屬公司 統稱「本集團」）根據香港聯合交易所有限公司證券上市規則（「《香港上市規則》」） 第13.10B條作出。 本次擔保不構成《香港上市規則》第14A章項下的關連交易或第14章項下的 須予公佈的交易。此外，《上海證券交易所上市公司自律監管指引第1號 — 規範運作》第6.2.10條規定上市公司控股子公司為上市公司合併報表範 圍內的法人或者其他組織提供擔保的，上市公司應當在控股子公司履行 審議程序後及時披露。由於本次擔保為本公司合併報表範圍內下屬子公 司之間的擔保，且擔保人已履行內部董事會決議程序，無須提交本公司董 事會或股東大會審議。 二、被擔保人基本情况 被擔保人的基本情況如下： ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-004 无锡药明康德新药开发股份有限公司 关于下属子公司之间提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为确保所有迫切需要 WuXi ATU 细胞治疗服务的客户和患者得到不受中断 的服务和及时救治，同时 WuXiATU 美国和英国业务的相关科学家、技术人员和 其他员工可继续为实现"让天下没有难做的药，难治的病"的使命持续工作，公 司全资子公司 ATU Ireland、ATU HK（即被担保人）与 Altaris LLC（包括其所控 制的主体，以下简称"Altaris"）于 2024 年 12 月 24 日（美国时间）签署《股权 购买协议》（SHARE PURCHASE AGREEMENT），分别将其持有的 WuXi Advanced Therapies Inc.（WuXi ATU 业务的美国运营主体，以下简称"Advanced Therapies"）全部股权及 Oxford Genetics Limited（WuXi ATU ...

呈交日期: 2025年3月3日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical industry [7] Core Views - The report highlights the performance of the Shenwan Pharmaceutical Index, which decreased by 2.72% during the week of February 24-28, 2024, outperforming the ChiNext Index but underperforming the CSI 300 Index. It emphasizes the identification of high-growth pharmaceutical companies for potential investment opportunities in 2024 [12][19] Summary by Sections Recent Review - The market showed stability in the first half of the week, with a significant drop on Friday. The technology sector faced adjustments, while the steel and food & beverage sectors performed well. The report notes that innovative drugs and companies with strong performance metrics are favorable, while AI medical applications experienced some adjustments [2][13] Future Outlook - The report suggests focusing on two main areas: market mapping related to AI applications in healthcare and policy expectations from the Two Sessions, such as fertility policies. It also emphasizes the ongoing innovation in the pharmaceutical sector, including international expansion and commercialization of early-stage innovative products [3][14] Strategy Configuration - The report outlines two strategic approaches: 1. **Pharmaceutical Style Rhythm**: Focus on innovative drugs such as BeiGene, Kelun-Biotech, and others, as well as AI medical applications like International Medical and Meinian Health [4][15] 2. **Pharmaceutical Industry Logic**: Emphasizes the commercialization of innovative drugs, new technologies, and internationalization strategies, including companies like Innovent Biologics and Hengrui Medicine [6][16] High-Growth Company Analysis - The report lists several high-growth pharmaceutical companies based on their 2024 performance forecasts, including BeiGene and BGI Genomics, noting that companies with strong quarterly performance are likely to maintain high growth throughout the year [19][22]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 | RMB | 387,076,150 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 2. 股份分類 | 普通股 | A 股份類別 | | ...